Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sunitinib.

Emma D Deeks1, Gillian M Keating

  • 1Wolters Kluwer Health/Adis, Auckland, New Zealand.

Drugs
|December 2, 2006
PubMed
Summary
This summary is machine-generated.

Sunitinib significantly improved progression-free survival in patients with advanced gastrointestinal stromal tumours (GIST) and renal cell carcinoma (RCC). This targeted therapy demonstrated superior efficacy compared to placebo and interferon-alpha in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Abrocitinib: First Approval.

Drugs·2022
Same author

Asciminib: First Approval.

Drugs·2022
Same author

Chiglitazar: First Approval.

Drugs·2021
Same author

Atogepant: First Approval.

Drugs·2021
Same author

Abrocitinib: First Approval.

Drugs·2021
Same author

Casirivimab/Imdevimab: First Approval.

Drugs·2021
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Sunitinib is a receptor tyrosine kinase inhibitor targeting tumor growth and angiogenesis.
  • Previous studies demonstrated sunitinib's efficacy in advanced gastrointestinal stromal tumors (GIST).

Purpose of the Study:

  • To evaluate the clinical efficacy of sunitinib in patients with advanced GIST and renal cell carcinoma (RCC).

Main Methods:

  • Phase III randomized, double-blind, placebo-controlled trial for imatinib-refractory GIST.
  • Phase II single-arm trials for cytokine-refractory metastatic RCC.
  • Phase III trial comparing sunitinib to interferon-alpha as first-line RCC therapy.

Main Results:

  • Sunitinib significantly increased time to tumor progression and progression-free survival in GIST patients compared to placebo.

Related Experiment Videos

  • In metastatic RCC, sunitinib showed significant progression-free survival benefits over interferon-alpha as a first-line treatment.
  • Partial responses and stable disease were observed in a substantial proportion of RCC patients.

    • Conclusions:

    • Sunitinib is an effective treatment for advanced GIST and metastatic RCC.
    • Sunitinib demonstrates superior efficacy compared to standard therapies like placebo and interferon-alpha.
    • Sunitinib is generally well-tolerated with mild to moderate adverse events.